SCHEDULE 13D/A 0001493152-25-002859 0002048828 XXXXXXXX LIVE 3 Common Stock, par value $0.001 per share 05/07/2025 false 0001795091 68764Y207 OS Therapies Inc

115 Pullman Crossing Road Suite #103 Grasonville MD 21638

Shalom Auerbach 917-364-7051 15 Atlantic Avenue, Suite M2 Lynbrook NY 11563 Einodmil LLC 917-364-7051 396 Oakland Avenue, Cedarhurst NY 11516 0002048828 N Shalom Auerbach AF PF N X1 2687570.00 0.00 2687570.00 0.00 2687570.00 N 9.9 IN See Item 5 for additional information. 0002048829 N Einodmil LLC WC N DE 2664199.00 0.00 2664199.00 0.00 2664199.00 N 9.8 OO See Item 5 for additional information. Common Stock, par value $0.001 per share OS Therapies Inc 115 Pullman Crossing Road Suite #103 Grasonville MD 21638 Item 1 of the Schedule 13D is hereby supplemented as follows: This Amendment No. 3 (this "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons (as defined in Item 2 of the Schedule 13D) with the SEC (as defined in Item 5 of the Schedule 13D) on January 17, 2025 (the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported on the Schedule 13D or the Schedule 13D/A filed by the Reporting Persons with the SEC on February 28, 2025 ("Amendment No. 1") and March 12, 2025 ("Amendment No. 2"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D, the Amendment No 1 and the Amendment No. 2, as applicable. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Item 3 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment and the information set forth in or incorporated by reference in Item 5 of this Amendment is hereby incorporated by reference in its entirety into this Item 3. On May 7, 2025, Einodmil sold 82,000 shares of Common Stock, which were effected on the open market at a weighted average price per share of approximately $1.9986 for proceeds of approximately $163,885 (the "May 7, 2025 Sales"). On April 10, 2025, Einodmil sold 10,000 shares of Common Stock, which were effected on the open market at a weighted average price per share of approximately $1.39 for proceeds of approximately $13,900 (the "April 10, 2025 Sales"). On April 9, 2025, Einodmil sold 50,012 shares of Common Stock, which were effected on the open market at a weighted average price per share of approximately $1.353 for proceeds of approximately $67,700 (the "April 9, 2025 Sales"). Item 5 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment is hereby incorporated by reference in its entirety into this Item 5. As of the date hereof, Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,687,570 shares of Common Stock, all of which Mr. Auerbach has sole voting and dispositive power. The holdings of Mr. Auerbach represent an aggregate of approximately 9.9% of the Issuer's outstanding shares of Common Stock (based on 27,202,661 shares of Common Stock issued and outstanding as reported directly by the Issuer to the Reporting Persons). As of the date hereof, Einodmil may be deemed to be the beneficial owner of an aggregate of 2,664,199 shares of Common Stock, all of which Einodmil has sole voting and dispositive power. The holdings of Einodmil represent an aggregate of approximately 9.8% of the Issuer's outstanding shares of Common Stock (based on 27,202,661 shares of Common Stock issued and outstanding as reported directly by the Issuer to the Reporting Persons). As of the date hereof, (i) Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,687,570 shares of Common Stock, all of which Mr. Auerbach has the sole voting and dispositive power, and (ii) Einodmil may be deemed to be the beneficial owner of an aggregate of 2,664,199 shares of Common Stock, all of which Einodmil has the sole voting and dispositive power. Except for the April 9, 2025 Sales, the April 10, 2025 Sales and the May 7, 2025 Sales, there were no other transactions by the Reporting Persons in shares of Common Stock during the period commencing sixty (60) days prior to the date hereof. Exhibit 1 - Joint Filing Agreement, dated as of January 17, 2025, signed by each of the Reporting Persons, incorporated by reference to Exhibit 1 to the Schedule 13D. Exhibit 2 - Transfer Agreement, dated as of May 13, 2024, by and between Einodmil and Paul Romness, incorporated by reference to Exhibit 2 to the Schedule 13D. Shalom Auerbach /s/ Shalom Auerbach 05/09/2025 Einodmil LLC /s/ Shalom Auerbach 05/09/2025